Brokerages Set Healthways Inc. (HWAY) Target Price at $26.08
Healthways Inc. (NASDAQ:HWAY) has received an average recommendation of “Hold” from the seven analysts that are currently covering the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $26.08.
HWAY has been the topic of a number of recent analyst reports. Zacks Investment Research raised Healthways from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a report on Thursday, November 3rd. Barclays PLC raised Healthways from an “underweight” rating to an “equal weight” rating and lifted their target price for the stock from $12.00 to $27.00 in a report on Monday, August 22nd. Jefferies Group lifted their target price on Healthways from $13.00 to $18.50 and gave the stock a “hold” rating in a report on Thursday, August 4th. Barrington Research reaffirmed an “outperform” rating and issued a $30.00 target price (up from $29.00) on shares of Healthways in a report on Thursday, October 13th. Finally, FBR & Co lifted their target price on Healthways from $16.00 to $21.00 and gave the stock an “outperform” rating in a report on Wednesday, August 10th.
In related news, CEO Donato Tramuto acquired 5,060 shares of Healthways stock in a transaction on Friday, November 4th. The shares were bought at an average cost of $19.95 per share, with a total value of $100,947.00. Following the completion of the purchase, the chief executive officer now directly owns 275,442 shares of the company’s stock, valued at approximately $5,495,067.90. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mary Jane England sold 3,600 shares of the business’s stock in a transaction that occurred on Friday, November 18th. The stock was sold at an average price of $22.26, for a total value of $80,136.00. Following the sale, the director now directly owns 30,871 shares in the company, valued at $687,188.46. The disclosure for this sale can be found here. Company insiders own 14.01% of the company’s stock.
Large investors have recently modified their holdings of the company. Acrospire Investment Management LLC raised its position in shares of Healthways by 80.9% in the second quarter. Acrospire Investment Management LLC now owns 9,612 shares of the company’s stock valued at $111,000 after buying an additional 4,300 shares during the period. Bank of Montreal Can raised its position in shares of Healthways by 610.2% in the third quarter. Bank of Montreal Can now owns 4,403 shares of the company’s stock valued at $116,000 after buying an additional 3,783 shares during the period. Quantitative Systematic Strategies LLC acquired a new position in shares of Healthways during the second quarter valued at about $118,000. Profund Advisors LLC raised its position in shares of Healthways by 4.5% in the second quarter. Profund Advisors LLC now owns 10,668 shares of the company’s stock valued at $123,000 after buying an additional 456 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its position in shares of Healthways by 7.6% in the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 11,685 shares of the company’s stock valued at $135,000 after buying an additional 825 shares during the period. 94.03% of the stock is currently owned by institutional investors.
Shares of Healthways (NASDAQ:HWAY) opened at 23.00 on Friday. Healthways has a 12-month low of $9.18 and a 12-month high of $27.30. The firm has a 50-day moving average price of $23.84 and a 200 day moving average price of $18.96. The stock’s market cap is $889.71 million.
Healthways (NASDAQ:HWAY) last posted its quarterly earnings results on Tuesday, November 1st. The company reported $0.30 EPS for the quarter, missing the Zacks’ consensus estimate of $0.52 by $0.22. The business had revenue of $125 million for the quarter, compared to the consensus estimate of $124.71 million. Healthways had a negative net margin of 24.50% and a positive return on equity of 13.49%. Healthways’s revenue was up 10.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.35 earnings per share. Equities research analysts expect that Healthways will post $1.64 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Brokerages Set Healthways Inc. (HWAY) Target Price at $26.08” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was copied illegally and reposted in violation of US and international trademark and copyright laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2016/11/23/brokerages-set-healthways-inc-hway-target-price-at-26-08.html.
Healthways Company Profile
Healthways, Inc (Healthways) provides network delivered solutions and population health management services that are designed to help people manage their wellbeing, thereby managing their health and productivity, and their health-related costs. The Company operates in the domestic and international segments, which are collectively known as the well-being improvement services segment.
Receive News & Stock Ratings for Healthways Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthways Inc. and related stocks with our FREE daily email newsletter.